Furthermore, ECGC, weakens the Tyr1068 EGFR phosphorylation so affecting the receptor recycling after lipid raft alteration [187], inhibiting the downstream effectors ERK and Akt and the transcriptional activity of AP-1, c-fos, NF-kB, and cyclin D1 promoters in colon cancer cells [162]. The gene discussed is AKT1; the disease is malignant colon neoplasm.